LEXINGTON, Mass.--(SynapDx Corporation is joining a select group of autism-focused companies to present at the inaugural Autism Investment Conference, held today in New York, NY and sponsored by Autism Speaks. SynapDx’s CEO Stanley Lapidus will share his vision for addressing the unmet needs in autism diagnosis as part of the panel entitled “Diagnostics and Enabling Technologies.” Lapidus will also update the community on SynapDx’s research efforts to further development of its breakthrough blood-based autism spectrum disorder (ASD) diagnostic test, designed to help clinicians identify children with autism earlier than they do today.)--
SynapDx’s blood-test approach measures differences in RNA gene expression to distinguish between children with a higher risk for ASDs from those without. The test could hasten the diagnostic process and help children at risk for ASDs secure access to the right evaluations and treatment as early as possible.
Open to investors, analysts and executives in the life sciences and healthcare, the Autism Investment Conference is designed to educate the investment community on the scale and diversity of business development opportunity in ASD. Through a series of panels, companies developing products aligned with unmet needs in ASD are able to showcase their efforts and network with investors.
Lapidus’ panel will take place today at 10:45 am ET.
About SynapDx Corp.
SynapDx is a private company providing laboratory diagnostics to physicians who suspect children of developmental disorders, with the initial goal of enabling earlier detection of autism spectrum disorders (ASDs). The company collaborates with ASD experts at leading institutions, including Boston Children’s Hospital. SynapDx was founded in 2010 and is based in Lexington, Mass. SynapDx’s investors include North Bridge Venture Partners, General Catalyst Partners and LabCorp.